FendX Files Provisional Patent for Novel Antimicrobial Nanoparticle Liquid Coating
FendX (OTCQB: FDXTF) filed a provisional patent application with the US Patent and Trademark Office for an "Antimicrobial Coating for Long-Lasting Pathogen Control on High-Touch Surfaces" (application no. 63/936,328), filed August 7, 2025, with FendX as assignee.
The application, prepared by Drs. Carolyn Myers, Tohid Didar, Leyla Soleymani and Sara Moetakef Imani, describes a novel nanoparticle liquid coating engineered for easy application (roller or brush) to actively disrupt microbial contamination and provide sustained protection on high-touch surfaces. The company said it is assessing scale-up and distribution partnership opportunities to commercialize the technology.
FendX (OTCQB: FDXTF) ha depositato una domanda di brevetto provvisorio presso l'US Patent and Trademark Office per una "Coating antimicrobico per un controllo prolungato dei patogeni su superfici ad alto contatto" (numero di domanda 63/936,328), presentata l'7 agosto 2025, con FendX in qualità di cessionaria.
La domanda, redatta dai dottori Carolyn Myers, Tohid Didar, Leyla Soleymani e Sara Moetakef Imani, descrive una nuova vernice nanostrutturata liquida progettata per un'applicazione facile (rullo o pennello) per interrompere attivamente la contaminazione microbica e fornire protezione sostenuta su superfici ad alto contatto. L'azienda ha dichiarato di valutare opportunità di scalatura e partnership di distribuzione per commercializzare la tecnologia.
FendX (OTCQB: FDXTF) presentó una solicitud de patente provisional ante la Oficina de Patentes y Marcas de EE. UU. para un "Recubrimiento antimicrobiano para un control duradero de patógenos en superficies de alto contacto" (número de solicitud 63/936,328), presentada el 7 de agosto de 2025, con FendX como cesionaria.
La solicitud, elaborada por los doctores Carolyn Myers, Tohid Didar, Leyla Soleymani y Sara Moetakef Imani, describe un novedoso recubrimiento líquido de nanopartículas diseñado para una fácil aplicación (rodillo o brocha) para interrumpir activamente la contaminación microbiana y proporcionar protección sostenida en superficies de alto contacto. La empresa dijo que está evaluando oportunidades de escalado y asociaciones de distribución para comercializar la tecnología.
펜드엑스(FendX) (OTCQB: FDXTF)가 미국 특허청에 고안된 "고접촉 표면에서 병원체를 장기간 제어하기 위한 항미생물 코팅"의 임시 특허 출원을 접수했습니다(출원 번호 63/936,328), 2025년 8월 7일 출원, 피출원인으로 FendX가 지정되었습니다.
본 출원은 Dr. Carolyn Myers, Tohid Didar, Leyla Soleymani 및 Sara Moetakef Imani 박사가 작성했으며, 쉽게 도포할 수 있도록 설계된 나노입자 액상 코팅으로 미생물 오염을 적극적으로 차단하고 고접촉 표면에 지속적인 보호를 제공하는 새로운 기술을 설명합니다. 회사는 이 기술의 상용화를 위한 규모 확대 및 유통 파트너십 기회를 평가 중이라고 밝혔습니다.
FendX (OTCQB: FDXTF) a déposé une demande de brevet provisoire auprès de l’Office américain des brevets et des marques pour un "Revêtement antimicrobien pour un contrôle durable des agents pathogènes sur les surfaces fréquemment touchées" (numéro de demande 63/936,328), déposée le 7 août 2025, avec FendX en tant qu’assignataire.
La demande, rédigée par les Drs. Carolyn Myers, Tohid Didar, Leyla Soleymani et Sara Moetakef Imani, décrit un nouveau revêtement liquide à base de nanoparticules conçu pour une application facile (rouleau ou pinceau) afin de perturber activement la contamination microbienne et de fournir une protection durable sur les surfaces fréquemment touchées. L’entreprise a indiqué qu’elle évaluait des opportunités de montée en échelle et de partenariats de distribution pour la commercialisation de la technologie.
FendX (OTCQB: FDXTF) hat beim US-Patent- und Markenamt eine vorläufige Patentanmeldung für ein "Antimikrobielle Beschichtung zur langanhaltenden Kontrolle von Krankheitserregern auf stark genutzten Oberflächen" (Anmeldenummer 63/936,328) eingereicht, am 7. August 2025, mit FendX als Zessionarin.
Die Anmeldung, erstellt von Dr. Carolyn Myers, Tohid Didar, Leyla Soleymani und Sara Moetakef Imani, beschreibt eine neuartige Nanopartikel-Flüssigbeschichtung, die für eine einfache Anwendung (Rolle oder Pinsel) entwickelt wurde, um mikrobielle Kontamination aktiv zu stören und einen nachhaltigen Schutz auf stark genutzten Oberflächen zu bieten. Das Unternehmen sagte, es prüfe Skalierungs- und Vertriebspartnerschaften zur Kommerzialisierung der Technologie.
فيندإكس (OTCQB: FDXTF) قدمت طلب براءة اختراع مبدئي لدى مكتب براءات الاختراع والعلامات التجارية الأمريكي لـ "طلاء مضاد للميكروبات للتحكم في مسببات الأمراض على الأسطح عالية اللمس لفترة طويلة" (رقم الطلب 63/936,328)، مقدم في 7 أغسطس 2025، مع تعيين فندإكس كمُحال إليه.
الطلب، الذي أعده الدكاترة كاريولين مايـرز، توهيد ديذار، ليلى سوليـيماني وسارة موِتاكي إماني، يصف طلاءًا سائلًا من الجسيمات النانوية محدثًا لتطبيق سهل (بكرة أو فرشاة) لعرقلة التلوث الميكروبي بنشاط وتوفير حماية مستدامة على الأسطح عالية اللمس. قالت الشركة إنها تقيم فرص توسيع النطاق وشراكات التوزيع لتسويق التكنولوجيا.
FendX (OTCQB: FDXTF) 已向美国专利商标局就一项 "高接触表面长期病原体控制的抗菌涂层" 提出一项临时专利申请（申请号63/936,328），于2025年8月7日提交，FendX为受让人。
该申请由Carolyn Myers、Tohid Didar、Leyla Soleymani和Sara Moetakef Imani博士撰写，描述了一种新型纳米粒子液态涂层，设计便于涂布（滚涂或刷涂），可主动破坏微生物污染，并在高接触表面提供持续保护。公司表示正在评估扩大规模和分销伙伴关系的机会，以实现该技术的商业化。
- None.
- None.
Vancouver, British Columbia--(Newsfile Corp. - October 22, 2025) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), an innovative surface protection company developing their technology-based solutions to reduce the spread of harmful pathogens and support a cleaner, safer world, is pleased to announce the filing of a provisional patent application with the United States Patent and Trademark Office. The application, titled "Antimicrobial Coating for Long-Lasting Pathogen Control on High-Touch Surfaces", assigned application number 63/936,328, was filed on August 7, 2025, by Drs. Carolyn Myers, Tohid Didar, Leyla Soleymani and Sara Moetakef Imani, with FendX as the assignee. This filing marks a significant addition to the Company's expanding portfolio of hygiene-related technologies.
The new application describes a novel nanoparticle liquid coating (formerly described as the spray technology) designed to provide long-lasting protection against a broad spectrum of pathogens found on high-touch surfaces. Engineered for easy application, using for example, a roller or brush, the coating leverages nanoparticle technology to actively disrupt microbial contamination, offering sustained efficacy in multiple settings.
"We are pleased with the progress of our development efforts on this liquid coating technology which have resulted in the filing of this patent application," said Dr. Carolyn Myers, CEO of FendX. "We are now actively assessing scale-up and distribution partnership opportunities to bring this technology to the market. This innovation underscores FendX's commitment to developing scalable solutions aimed at reducing infection risk."
About FendX Technologies Inc.
FendX is a surface protection company leveraging its proprietary technology to develop product solutions that help reduce the spread of harmful pathogens in everyday environments. The Company is advancing its pipeline of products under development which includes REPELWRAP™ film, a protective surface coating with repelling properties that significantly reduce adhesion and transmission of pathogens on high-touch surfaces, and nanoparticle infused liquid coating with similar functionality. Additionally, the Company is developing specialized catheter coatings, with its first coating being for Foley catheters. The Company holds exclusive worldwide licenses and intellectual property for its coating technologies.
ON BEHALF OF THE COMPANY
"Carolyn Myers"
Carolyn Myers
Chief Executive Officer and Director
Contacts:
Dr. Carolyn Myers, CEO and Director
1-800-344-9868
investor@fendxtech.com
For more information, please visit https://fendxtech.com/ and the Company's profile on SEDAR+ at www.sedarplus.ca.
Neither the Canadian Securities Exchange nor the Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains certain forward-looking statements within the meaning of Canadian securities legislation, including with respect to: the plans of the Company; statements regarding the provisional patent application, the nanoparticle liquid coating technology, including the proposed easy application methods using for example a roller or brush, the proposed benefits of, efficacy and goals related to the development of the technology; statements regarding the Company actively assessing scale-up and distribution partnership opportunities to bring this technology to the market; and products under development and any pathogen reduction benefits related thereto. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. These statements are only predictions and involve known and unknown risks which may cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking statements, including: risks that the provisional patent application may not receive regulatory approval; adverse market conditions; risks and uncertainties associated with the Company's ability to raise additional capital to complete all of its planned activities including development and scale-up of the nanoparticle liquid coating; risks related to research and development activities for each of the film, nanoparticle liquid coating formulation and catheter coating, including successful completion of real world performance testing and scale-up initiatives; risks that the Company may not expand its product pipeline or execute its business development and growth plans; risks that the Company will be unsuccessful in entering into distribution partnerships to market its products; risks that the Company's products may not be commercialized, and if they are commercialized, that they may not be accepted and adopted by the public; the risk that the Company will not obtain necessary approvals and/or clearances as anticipated or at all; the effects of government regulation on the Company's business; risks associated with the Company's ability to obtain and protect rights to its intellectual property; product candidates only being in formulation/reformulation stages; limited operating history; dependence on collaborative partners, licensors and others; effect of general economic and political conditions; and other factors beyond the Company's control. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity or performance. Further, any forward-looking statement speaks only as of the date on which such statement is made and, except as required by applicable law, the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for management to predict all of such factors and to assess in advance the impact of such factors on the Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. Readers should consult all of the information set forth herein and should also refer to the risk factor disclosure outlined in the Company's filings with the British Columbia Securities Commission on SEDAR+ at www.sedarplus.ca.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/271383
FAQ
What did FendX (FDXTF) file on August 7, 2025?
Who are the inventors listed on FendX's provisional patent for the coating?
What does the FendX (FDXTF) patent application describe?
How might the provisional patent filing affect FendX shareholders (FDXTF)?
Is FendX (FDXTF) ready to commercialize the nanoparticle coating now?
Where was FendX's provisional patent filed and what is its title?
